REGULATORY STATUS & ACCESS · GHK-Cu / BPC-157 / TB-500
GLOW Legal Status, FDA 503A Category, and Compounding Access
Access to GLOW's peptide constituents is under active FDA review and may expand in 2026 — but as the record stands today they are FDA Category 2 bulk substances, and compounding access is restricted. The present-tense facts, cited to FDA.
GLOW legal status: where peptide access stands, and where it is heading
GLOW legal status turns on its constituents, and the most important context is forward-looking: access to these peptides is under active FDA review and may expand in 2026. The U.S. Food and Drug Administration has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23-24, 2026 to discuss BPC-157 and TB-500 as candidates "being considered for inclusion on the 503A Bulks List" [13]. That is a scheduled evaluation of substances under review — momentum in the process — not a decision, a reclassification, or a dated outcome.
As the record stands today, the present-tense fact is narrower. GLOW's injectable peptide constituents are research peptides that FDA placed in its 503A "Category 2" — bulk substances FDA has identified as raising significant safety risks — effective with the September 29, 2023 update to the nominated-substances list [12]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, so compounding-pharmacy access to them is currently restricted [11][12]. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply any substance.
The 503A and 503B framework, in brief
Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection [11].
A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than a finished FDA-approved drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [11]. Substances not yet on a bulks list are evaluated through a public nomination process with input from PCAC. Being discussed by PCAC is a step in that evaluation, not a final listing decision [11][13]. None of GLOW's three peptide constituents is an FDA-approved drug.
None of GLOW's constituents is an FDA-approved drug. Category 2 status means FDA has identified significant safety risks for the bulk substance and would consider action against a compounder using it; it is not approval for any use [12].
Where each GLOW constituent stands today
BPC-157. FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update, citing concerns including potential immunogenicity for certain routes and complexities with peptide-related impurities and characterization [12]. As a Category 2 substance it is not within FDA's enforcement-discretion policy. BPC-157 is on the published agenda of the July 23-24, 2026 PCAC meeting as a substance being considered for the 503A bulks list — a scheduled discussion, not a change in current status [13].
TB-500 (thymosin beta-4 fragment). FDA identified "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" as a bulk substance that may present significant safety risks and placed it in Category 2, effective with the same September 29, 2023 update, citing immunogenicity concerns for certain routes and a lack of important safety information [12]. FDA's own list entry establishes that TB-500 is the LKKTETQ fragment associated with thymosin beta-4. TB-500 also appears on the July 23-24, 2026 PCAC agenda as a candidate under evaluation [13].
GHK-Cu (copper peptide). Two regulatory contexts must be kept separate. As a cosmetic, GHK-Cu is labeled "Copper Tripeptide-1" and used as a topical ingredient; cosmetic ingredients are regulated under cosmetics rules and are not subject to FDA pre-market drug approval [15]. As an injectable drug, FDA identified "GHK-Cu (for injectable routes of administration)" as a bulk substance that may present significant safety risks and placed it in Category 2, effective with the September 29, 2023 update [12]. Injectable GHK-Cu is not on the July 23-24, 2026 PCAC agenda, and its injectable form remains Category 2 — separate from the legal cosmetic Copper Tripeptide-1 [13].
FDA Category 2 entries effective 2023-09-29: BPC-157; "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; "GHK-Cu (for injectable routes of administration)." PCAC agenda 2026-07-23/24 lists BPC-157 and TB-500; not GHK-Cu [12][13].
How legally compounded peptide access works
Where a substance is eligible for compounding, the lawful access path follows a fixed order. First, a patient is evaluated by an appropriately licensed prescriber — in person or via a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [11]. Telehealth is one channel for that prescriber-evaluation step; it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not expand which substances may be compounded [11].
If the preparation is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility [11]. The ingredient-eligibility caveat governs the whole path: the compounder may use the requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules, and ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [11][12]. This is general information; it is not a description of how to obtain a restricted substance.
Lawful pathway, general terms: licensed-prescriber evaluation (telehealth as a possible front-end channel) → valid patient-specific prescription → 503A compounding pharmacy or 503B outsourcing facility — subject to the ingredient being eligible under the bulk-substance rules [11].
Is GLOW legal?
GLOW is not an FDA-approved drug. Its injectable peptide constituents — BPC-157, TB-500 and injectable GHK-Cu — are FDA Category 2 bulk substances, identified as raising significant safety risks and not covered by FDA's enforcement-discretion policy for 503A compounding, effective with the September 29, 2023 list update [12]. Topical Copper Tripeptide-1 is regulated separately as a cosmetic [15].
Can you get GHK-Cu from a compounding pharmacy?
Injectable GHK-Cu is in FDA Category 2 for 503A compounding, effective with the September 29, 2023 update, so it is not within FDA's enforcement-discretion policy and access is currently restricted [12]. The separate topical cosmetic ingredient Copper Tripeptide-1 is regulated under cosmetics rules and is a different question from injectable-drug compounding [15].
What is the FDA 503A status of GLOW?
GLOW has no status as a blend; status attaches to each constituent. BPC-157, TB-500 and injectable GHK-Cu are each in 503A Category 2 (significant safety risks), effective September 29, 2023 [12]. BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda as candidates under evaluation — a scheduled discussion, not a decision [13].